News
LENZ
6.79
+1.04%
0.07
Weekly Report: what happened at LENZ last week (0601-0605)?
Weekly Report · 1d ago
Everest Medicines Acquires Rights To Develop And Commercialize VIZZ In Greater China
NASDAQ · 1d ago
Everest Medicines acquires Greater China rights for LENZ Therapeutics' presbyopia eyedrop VIZZ®
Seeking Alpha · 1d ago
Lenz announces Everest Medicines acquired rights to develop VIZZ in China
TipRanks · 1d ago
LENZ THERAPEUTICS ANNOUNCES EVEREST MEDICINES ACQUIRED RIGHTS TO DEVELOP AND COMMERCIALIZE VIZZ® (LNZ100) IN GREATER CHINA
Reuters · 1d ago
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
Barchart · 2d ago
Amgen: Time For An Upgrade? Yes, I Think So
Seeking Alpha · 4d ago
Where short sellers are betting in micro- and small-cap stocks
Seeking Alpha · 5d ago
William Blair updates its Conviction List
Seeking Alpha · 06/02 09:19
Weekly Report: what happened at LENZ last week (0525-0529)?
Weekly Report · 06/01 10:24
LENZ Therapeutics to attend William Blair growth stock conference for investor meetings
PUBT · 05/26 12:03
Weekly Report: what happened at LENZ last week (0518-0522)?
Weekly Report · 05/25 10:28
Weekly Report: what happened at LENZ last week (0511-0515)?
Weekly Report · 05/18 10:27
Some LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Just Made A Major Cut To Next Year's Estimates
Simply Wall St · 05/16 14:11
Earnings Update: LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Are Trimming Their Forecasts
Simply Wall St · 05/14 13:02
LENZ Therapeutics Is Maintained at Buy by Citigroup
Dow Jones · 05/13 18:58
LENZ Therapeutics Price Target Cut to $20.00/Share From $26.00 by Citigroup
Dow Jones · 05/13 18:58
Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $20
Benzinga · 05/13 18:48
Lenz Therapeutics price target lowered to $20 from $26 at Citi
TipRanks · 05/13 10:43
LENZ Therapeutics trading resumes
TipRanks · 05/12 19:21
More
Webull provides a variety of real-time LENZ stock news. You can receive the latest news about LENZ THERAPEUTICS INC through multiple platforms. This information may help you make smarter investment decisions.
About LENZ
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.